AVEO Pharmaceuticals (DB:VPA1) - Aandelenkoers, Nieuws & Analyse

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

VPA1 Overzicht aandelen

AVEO Pharmaceuticals, Inc., an oncology-focused biopharmaceutical company, focuses on developing and commercializing medicines for patients with cancer.

Over het bedrijf

VPA1 fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	5/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De winst zal naar verwachting met 123% per jaar groeien

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Risicoanalyse

Geen risico's gedetecteerd voor VPA1 uit onze risicocontroles.

AVEO Pharmaceuticals, Inc. Concurrenten

Formycon

XTRA:FYB

€821.0m

Heidelberg Pharma

XTRA:HPHA

€116.5m

MorphoSys

XTRA:MOR

€2.5b

Biotest

XTRA:BIO3

€1.4b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor AVEO Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers	US$13.77
52 Week Hoogtepunt	US$15.17
52 Week Laag	US$2.80
Bèta	0.98
11 maand verandering	-1.36%
3 maanden verandering	-7.83%
1 Jaar Verandering	358.69%
33 jaar verandering	155.00%
5 jaar verandering	-43.57%
Verandering sinds IPO	-78.52%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	VPA1	DE Biotechs	DE Markt
7D	0.7%	-3.1%	-1.0%
1Y	358.7%	-15.2%	16.1%

Rendement versus industrie: VPA1 overtrof de German Biotechs industrie, die het afgelopen jaar een rendement -15.2 % opleverde.

Rendement versus markt: VPA1 overtrof de German markt, die het afgelopen jaar een rendement opleverde van 16.1 %.

Prijsvolatiliteit

Is VPA1's price volatile compared to industry and market?
VPA1 volatility
VPA1 Average Weekly Movement	1.9%
Biotechs Industry Average Movement	6.2%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.5%

Stabiele aandelenkoers: De aandelenkoers van VPA1 is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van VPA1 is het afgelopen jaar gedaald van 11% naar 2%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2001	114	Michael Bailey	www.aveooncology.com

AVEO Pharmaceuticals, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van AVEO Pharmaceuticals zich tot de beurswaarde?
VPA1 fundamentele statistieken
Marktkapitalisatie	€480.25m
Inkomsten(TTM)	-€26.74m
Inkomsten(TTM)	€86.87m

5.5x

P/S-verhouding

-18.0x

Koers/Winstverhouding

Is VPA1 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
VPA1 resultatenrekening (TTM)
Inkomsten	US$94.32m
Kosten van inkomsten	US$37.79m
Brutowinst	US$56.53m
Overige uitgaven	US$85.56m
Inkomsten	-US$29.04m

Laatst gerapporteerde inkomsten

Sep 30, 2022

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.84
Brutomarge	59.93%
Nettowinstmarge	-30.79%
Schuld/Eigen Vermogen Verhouding	134.1%

Hoe presteerde VPA1 op de lange termijn?

Bekijk historische prestaties en vergelijking

This company listing is no longer active

VPA1 Overzicht aandelen

Beloningen

Risicoanalyse

AVEO Pharmaceuticals, Inc. Concurrenten

XTRA:FYB

€821.0m

XTRA:HPHA

€116.5m

XTRA:MOR

€2.5b

XTRA:BIO3

€1.4b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

LG Chem, Ltd. (KOSE:A051910) completed the acquisition of AVEO Pharmaceuticals, Inc. (NasdaqCM:AVEO) from a group of shareholders.

AVEO Oncology Appoints Martin Birkhofer as Its Chief Medical Officer

Insufficient new directors

Third quarter 2022 earnings released: US$0.094 loss per share (vs US$0.30 loss in 3Q 2021)

Aveo Pharmaceuticals, Inc. Withdraws Earnings Guidance for the Year 2022

AVEO Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Recent updates

LG Chem, Ltd. (KOSE:A051910) completed the acquisition of AVEO Pharmaceuticals, Inc. (NasdaqCM:AVEO) from a group of shareholders.

AVEO Oncology Appoints Martin Birkhofer as Its Chief Medical Officer

Insufficient new directors

Third quarter 2022 earnings released: US$0.094 loss per share (vs US$0.30 loss in 3Q 2021)

Aveo Pharmaceuticals, Inc. Withdraws Earnings Guidance for the Year 2022

AVEO Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 07, 2022

AVEO Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Full Year 2022

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.40 loss in 2Q 2021)

AVEO Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022

AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from Russell Microcap Value Index

AVEO Oncology Announces Updated National Comprehensive Cancer Network Clinical Practice Guidelines Elevate Fotivda (Tivozanib) to Category 1 Treatment for Relapsed or Refractory Advanced Renal Cell Carcinoma Patients

First quarter 2022 earnings released: US$0.30 loss per share (vs US$0.81 loss in 1Q 2021)

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

AVEO Pharmaceuticals, Inc. Announces Positive New Long-Term PFS Data from Phase 3 TIVO-3 Study of FOTIVDA® in Third- and Fourth-Line Renal Cell Carcinoma

Aveo Oncology Presents Three Posters for Tivozanib/Immunotherapy Combinations at the 2022 ASCO GI Cancers Symposium

Aveo Oncology Highlights Recent Progress and 2022 Outlook

Third quarter 2021 earnings released: US$0.30 loss per share (vs US$0.33 loss in 3Q 2020)

AVEO Oncology Announces Ficlatuzumab Grants Fast Track Designation by the U.S. FDA

AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from Russell 3000E Value Index

AVEO Oncology Announces Positive Results from Randomized Phase 2 Study of Ficlatuzumab in Combination with Cetuximab in Pan-Refractory, Metastatic HNSCC

CANbridge Life Sciences Ltd. and AVEO Pharmaceuticals, Inc. Terminate Collaboration and License Agreement

AVEO Oncology Announces Collaboration with Bristol Myers Squibb to Evaluate Fotivda® in Combination with Opdivo® in Pivotal Phase 3 Tinivo-2 Trial in Io Relapsed Renal Cell Carcinoma

AVEO Oncology Announces U.S. FDA Approval of FOTIVDA (tivozanib) for the Treatment of Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma

AVEO Oncology Announces Appointment of Mike Ferraresso to Chief Commercial Officer

AVEO Pharmaceuticals, Inc. Appoints Corinne Epperly as Member of the Board and to Its Nominating and Governance Committee and Compensation Committee

AVEO Pharmaceuticals, Inc. Announces the Departure of Karuna Rubin, Senior Vice President and General Counsel

AVEO Oncology Announces Results from Phase 1b Portion of DEDUCTIVE Study of Tivozanib (FOTIVDA®) in Combination with IMFINZI® (Durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma

AVEO Pharmaceuticals, Inc. Announces Management Changes

AVEO Oncology and EUSA Pharma Announce Annals of Oncology Publication of Data from Phase 1b/2 TiNivo Study in Renal Cell Carcinoma

AVEO Pharmaceuticals, Inc. announced that it has received $7.499997 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from S&P Global BMI Index

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

AVEO Pharmaceuticals, Inc. Samenvatting

5.5x

-18.0x

Inkomsten en omzet